Detalles de la búsqueda
1.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34140638
2.
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Invest New Drugs
; 37(2): 271-281, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30073466
3.
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Blood
; 119(24): 5772-81, 2012 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22538852
4.
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-ß monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
J Immunother Cancer
; 11(11)2023 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38030303
5.
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Blood
; 116(17): 3227-37, 2010 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-20651070
6.
Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Haematologica
; 97(4): 482-90, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22058218
7.
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Mol Cancer Ther
; 21(4): 625-634, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35131875
8.
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Clin Cancer Res
; 28(6): 1087-1097, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921024
9.
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Clin Cancer Res
; 28(5): 870-881, 2022 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34862243
10.
Translational Modeling of Anticancer Efficacy to Predict Clinical Outcomes in a First-in-Human Phase 1 Study of MDM2 Inhibitor HDM201.
AAPS J
; 23(2): 28, 2021 02 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554304
11.
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Cancer Res
; 81(11): 3079-3091, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33504557
12.
Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Apoptosis
; 20(12): 1666-7, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26400497
13.
Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Eur J Cancer
; 126: 93-103, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31927215
14.
TGFß-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.
Nat Commun
; 11(1): 6315, 2020 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33298926
15.
Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia.
Apoptosis
; 13(9): 1148-61, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18670883
16.
Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103].
Eur J Cancer
; 184: 199, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36868971
17.
PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor.
Oncogene
; 24(51): 7503-13, 2005 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-16091749
18.
Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Cancer Chemother Pharmacol
; 74(5): 1057-64, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25217392
19.
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
Clin Cancer Res
; 25(9): 2938, 2019 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31043386
20.
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Clin Lymphoma Myeloma Leuk
; 13(4): 370-6, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23787122